Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation

Usefulness of Transcatheter Aortic Valve Implantation for Treatment of Pure Native Aortic Valve Regurgitation

Patients with pure native aortic valve regurgitation (NAVR) and increased surgical risk are often denied surgery. This retrospective study aimed to evaluate the “off-label” use of transcatheter heart valves (THV) for the treatment of NAVR. A total of 254 high surgical risk patients with NAVR (age 74...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of cardiology 2018-09, Vol.122 (6), p.1028-1035
Hauptverfasser: De Backer, Ole, Pilgrim, Thomas, Simonato, Matheus, Mackensen, G. Burkhard, Fiorina, Claudia, Veulemanns, Verena, Cerillo, Alfredo, Schofer, Joachim, Amabile, Nicolas, Achkouty, Guy, Schäfer, Ulrich, Deutsch, Marcus-André, Sinning, Jan-Malte, Rahman, Mohammed S., Sawaya, Fadi J., Hildick-Smith, David, Hernandez, Jose Maria, Kim, Won-Keun, Lefevre, Thierry, Seiffert, Moritz, Bleiziffer, Sabine, Petronio, Anna Sonia, Van Mieghem, Nicolas, Taramasso, Maurizio, Søndergaard, Lars, Windecker, Stephan, Latib, Azeem, Dvir, Danny
Format: Artikel
Sprache:eng
Schlagworte:
Aortic valve
Clinical outcomes
Consortia
Endocarditis
Heart valves
Implantation
Medical personnel
Mortality
Patients
Regurgitation
Risk
Risk groups
Stroke
Success
Surgery
Thorax
Transplants & implants
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Patients with pure native aortic valve regurgitation (NAVR) and increased surgical risk are often denied surgery. This retrospective study aimed to evaluate the “off-label” use of transcatheter heart valves (THV) for the treatment of NAVR. A total of 254 high surgical risk patients with NAVR (age 74 ± 12 years, Society of Thoracic Surgeons risk score 6.6 ± 6.2%) underwent transcatheter aortic valve implantation (TAVI) with early generation (43%) or newer generation (57%) devices at 46 different sites. Device success was significantly higher in patients treated with newer as compared with early generation THV (82% vs 47%, p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2018.05.044